|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Retrograde-viewing device improves adenoma detection rate in colonoscopies for surveillance and diagnostic workup显示文摘AIM:To determine which patients might benefit most from retrograde viewing during colonoscopy through subset analysis of randomized,controlled trial data.METHODS:The Third Eye Retroscope Randomized Clinical Evaluation(TERRACE) was a randomized,controlled,multicenter trial designed to evaluate the efficacy of a retrograde-viewing auxiliary imaging device that is used during colonoscopy to provide a second video image which allows viewing of areas on the proximal aspect of haustral folds and flexures that are difficult to see with the colonoscope's forward view.We performed a post-hoc analysis of the TERRACE data to determine whether certain subsets of the patient population would gain more benefit than others from use of the device.Subjects were patients scheduled for colonoscopy for screening,surveillance or diagnostic workup,and each underwent same-day tandem examinations with standard colonoscopy(SC) and Third Eye colonoscopy(TEC),randomized to SC followed by TEC or vice versa.RESULTS:Indication for colonoscopy was screening in 176/345 subjects(51.0%),surveillance after previous polypectomy in 87(25.2%) and diagnostic workup in 82(23.8%).In 4 subjects no indication was specified.Previously reported overall results had shown a net additional adenoma detection rate(ADR) with TEC of 23.2% compared to SC.Relative risk(RR) of missing adenomas with SC vs TEC as the initial procedure was 1.92(P = 0.029).Post-hoc subset analysis shows additional ADRs for TEC compared to SC were 4.4% for screening,35.7% for surveillance,55.4% for diagnostic and 40.7% for surveillance and diagnostic combined.The RR of missing adenomas with SC vs TEC was 1.11(P = 0.815) for screening,3.15(P = 0.014) for surveillance,8.64(P = 0.039) for diagnostic and 3.34(P = 0.003) for surveillance and diagnostic combined.Although a multivariate Poisson regression suggested gender as a possibly significant factor,subset analysis showed that the difference between genders was not statistically significant.Age,bowel prep quality and withdrawal time did not significantly affect the RR of missing adenomas with SC vs TEC.Mean sizes of adenomas detected with TEC and SC were similar at 0.59 cm and 0.56 cm,respectively(P = NS).CONCLUSION:TEC allows detection of significantly more adenomas compared to SC in patients undergoing surveillance or diagnostic workup,but not in screening patients(ClinicalTrials.gov Identifier:NCT01044732). | Peter D Siersema Amit Rastogi Anke M Leufkens Paul A Akerman Kassem Azzouzi Richard I Rothstein Frank P Vleggaar Alessandro Repici Giacomo Rando Patrick I Okolo Olivier Dewit Ana Ignjatovic Elizabeth Odstrcil James East Pierre H Deprez Brian P Saunders Anthony N Kalloo Bradley Creel Vikas Singh Anne Marie Lennon Daniel C DeMarco | 2012 | World Journal of Gastroenterology2012，18，26： | 6 |
| 2 | Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1显示文摘Fibroblast growth factor 2(FGF-2)is overexpressed in a subset of invasive bladder carcinomas and its overexpression correlates with poor prognosis.Analyses of publicly available databases addressing the molecular mechanisms that may be responsible for the poor prognosis of these tumors,revealed that FGF-2 expression correlates positively with the expression of epithelial to mesenchymal transition(EMT)-promoting transcription factors and with changes in gene expression that are characteristic of EMT.The same analyses also revealed that FGF-2 correlates negatively with the expression,mutation and copy number variations of FGFR-3,all of which are associated with noninvasive bladder carcinomas.Finally,they showed that FGF-2 expression correlates with the expression of FGFR-1,the expression of the IIIc variant of FGFR-2 and with the expression of Akt3.The latter observation is significant because our earlier studies had shown that Akt3 regulates FGFR-2 alternative splicing,shifting the balance toward the IIIc relative to the IIIb FGFR-2 splice variant.As the IIIc variant is recognized by FGF-2,while the IIIb variant is not,we conclude that Akt3 may facilitate the FGF-2 response.FGF-2 is known to promote the expression of KDM2B,which functions in concert with EZH2 to repress the EZH2-targeting microRNA miR-101,activating a switch,which stably upregulates EZH2.The cancer genome atlas(TCGA)data showing a correlation between KDM2B and EZH2 expression and Oncomine data,showing a correlation between KDM2B and tumor progression,strongly support the role of the FGF-2/KDM2B/miR-101/EZH2 pathway in bladder cancer.These observations combined,suggest a model according to which FGF-2 induces EMT,cell proliferation and cancer stem cell self-renewal by coupling the Akt3 and KDM2B-controlled pathways outlined above,in bladder carcinomas.Further analyses of publicly available databases,revealed that FGF-2-expressing bladder carcinomas carry fewer genetic alterations and they tend to express high levels of CTLA-4,PD-1 and PD-L1,which suggests immune blockade by checkpoint activation.EMT,enhanced proliferation and immune checkpoint activation combined,may be responsible for the poor prognosis of FGF-2-expressing bladder carcinomas. | Elizabeth A McNiel Philip N Tsichlis | 2017 | Signal Transduction and Targeted Therapy2017，2，1： | 6 |
| 3 | Cancer stem cell impact on clinical oncology显示文摘Cancer is a widespread worldwide chronic disease. In most cases, the high mortality rate from cancer correlates with a lack of clear symptoms, which results in late diagnosis for patients, and consequently, advanced tumor disease with poor probabilities for cure, since many patients will show chemo-and radio-resistance. Several mechanisms have been studied to explain chemo-and radio-resistance to anti-tumor therapies, including cell signaling pathways, anti-apoptotic mechanisms, stemness, metabolism, and cellular phenotypes. Interestingly, the presence of cancer stem cells(CSCs), which are a subset of cells within the tumors, has been related to therapy resistance. In this review, we focus on evaluating the presence of CSCs in different tumors such as breast cancer, gastric cancer, lung cancer, and hematological neoplasias, highlighting studies where CSCs were identified in patient samples. It is evident that there has been a great drive to identify the cell surface phenotypes of CSCs so that they can be used as a tool for anti-tumor therapy treatment design. We also review the potential effect of nanoparticles, drugs, natural compounds, aldehyde dehydrogenase inhibitors, cell signaling inhibitors, and antibodies to treat CSCs from specific tumors. Taken together, we present an overview of the role of CSCs in tumorigenesis and how research is advancing to target these highly tumorigenic cells to improve oncology patient outcomes. | Mariel E Toledo-Guzmán Gabriele D Bigoni-Ordonez Miguel Ibanez Hernandez Elizabeth Ortiz-Sánchez | 2018 | World Journal of Stem Cells2018，10，12： | 4 |
| 4 | Metabolic syndrome does not affect sustained virologic response of direct-acting antivirals while hepatitis C clearance improves hemoglobin A1c显示文摘AIM To determine whether successful treatment with direc-tacting antivirals(DAA) is associated with improvements in hemoglobin A1 c(HbA1 c) and if type 2 diabetes mellitus(T2 DM) or metabolic syndrome affects sustained virologic response(SVR).METHODS We performed a retrospective analysis of all hepatitis C virus(HCV) patients at the VA Greater Los Angeles Healthcare System treated with varying DAA therapy between 2014-2016. Separate multivariable logistic regression was performed to determine predictors of HbA1 c decrease ≥ 0.5 after DAA treatment and predictors of SVR 12-wk post treatment(SVR12).RESULTS A total of 1068 patients were treated with DAA therapy between 2014-2016. The presence of T2 DM or metabolic syndrome did not adversely affect SVR12. 106 patients had both HCV and T2 DM. Within that cohort,patients who achieved SVR12 had lower mean HbA1 c pre treatment(7.35 vs 8.60,P = 0.02),and lower mean HbA1 c post-treatment compared to non-responders(6.55 vs 8.61,P = 0.01). The mean reduction in HbA1 c after treatment was greater for those who achieved SVR12 than for non-responders(0.79 vs 0.01,P = 0.03). In adjusted models,patients that achieved SVR12 were more likely to have a HbA1 c decrease of ≥ 0.5 than those that did not achieve SVR12(adjusted OR = 7.24,95%CI: 1.22-42.94). CONCLUSION In HCV patients with T2 DM,successful treatment with DAA was associated with a significant reduction in HbA1 c suggesting that DAA may have a role in improving insulin sensitivity. Furthermore,the presence of T2 DM or metabolic syndrome does not adversely affect SVR12 rates in patients treated with DAA. | Tien S Dong Elizabeth S Aby Jihane N Benhammou Jenna Kawamoto Steven-Huy Han Folasade P May Joseph R Pisegna | 2018 | World Journal of Hepatology2018，10，9： | 4 |
| 5 | Reproducibility of the diagnosis of dysplasia in Barrett esophagus: A reaffirmation显示文摘 | Elizabeth Montgomery Mary P Bronner John R Goldblum Joel K Greenson Marian M Haber John Hart Laura W Lamps Gregory Y Lauwers Audrey J Lazenby David N Lewin Marie E Robert Alicia Y Toledano Yu Shyr Kay Washington | 2001 | Human Pathology2001，，4： | 3 |
| 6 | Randomised controlled trial of combined spinal epidural vs. spinal anaesthesia for elective caesarean section: vasopressor requirements and cardiovascular changes显示文摘 | Alan JR Macfarlane Artur Pryn Kerry N Litchfield Fiona Bryden Steven Young Christopher Weir Elizabeth M McGrady | 2009 | European Journal of Anaesthesiology2009，，1： | 2 |
| 7 | MicroRNAs in biliary diseases显示文摘Cholangiopathies are a group of diseases primarily or secondarily affecting bile duct cells, and result in cholangiocyte proliferation, regression, and/or transformation. Their etiopathogenesis may be associated with a broad variety of causes of different nature, which includes genetic, neoplastic, immune-associated, infectious, vascular, and drug-induced alterations, or being idiopathic. miRNAs, small non-coding endogenous RNAs that post-transcriptionally regulate gene expres sion, have been associated with pathophysiological processes in different organs and cell types, and are postulated as potential targets for diagnosis and therapy. In the current manuscript, knowledge regarding the role of miRNAs in the development and/or progression of cholangiopathies has been reviewed and the most relevant findings in this promising field of hepatology have been highlighted. | Patricia Munoz-Garrido Maite García-Fernández de Barrena Elizabeth Hijona Miguel Carracedo JoséJ G Marín Luis Bujanda Jesús M Banales | 2012 | World Journal of Gastroenterology2012，18，43： | 2 |
| 8 | Cause-related marketing How generation Y responds 显示文摘 | Cui Yanli Trent Elizabeth S Sullivan Pauline M Matiru Grace N | 2003 | International Journal of Retail & Distribution Management2003，31，67： | 1 |
| 9 | Global Iodine Nutrition: Where Do We Stand in 2013显示文摘 | Elizabeth N Pearce | 2013 | 23(5):407-4092013，23，5： | 1 |
| 10 | Probiotics and prebiotics in dermatology显示文摘 | Katherine L Baquerizo N Elizabeth Y | 2014 | Journal of American Academy of Dermatology2014，71，4： | 1 |
| 11 | Association Between Acute Statin Therapy, Survival, and Improved Functional Outcome After Ischemic Stroke: The North Dublin Population Stroke Study显示文摘 | Danielle Ní Chróinín Elizabeth L. Callaly Joseph Duggan áine Merwick Niamh Hannon órla Sheehan Michael Marnane Gillian Horgan Emma B. Williams Dawn Harris Lorraine Kyne Patricia M.E. McCormack Joan Moroney Tim Grant David Williams Leslie Daly Peter J. Kel | 2011 | Stroke2011，，： | 1 |
| 12 | Cloning and characterization of an esophageal-gland-specific pectate lyase from the root-knot nematode Meloidogyne javanica 显示文摘 | Doyle Elizabeth A Lambert Kris N | 2002 | Molecular Plant-Microbe Interactions2002，15，6： | 1 |
| 13 | Structure and partial genomic sequence of the human E2F1 gene 显示文摘 | Elizabeth N William RS John AM | 1996 | Gene1996，173，2： | 1 |
| 14 | Expression of critical illness and association with multiorgan dysfunction severity and survival显示文摘 | Elizabeth D E Papathanassoglon R N Jan A | 2001 | Crit Care Med2001，29，： | 1 |
| 15 | Total hip replacement due to osteoarthritis: the importance of age, obesity, and other modifiable risk factors显示文摘 | Elizabeth W Karlson Lisa A Mandl Gideon N Aweh Oliver Sangha Matthew H Liang Francine Grodstein | 2003 | The American Journal of Medicine2003，，2： | 1 |
| 16 | Purification and Identification of antihypertensive peptides in Spanish dry-cured ham显示文摘 | Elizabeth Escudero Leticia Mora Paul D. Fraser María-Concepción Aristoy Keizo Arihara Fidel Toldrá | 2012 | Journal of Proteomics2012，，： | 1 |
| 17 | Green fluorescent protein as a quantitative tool显示文摘 | Nicola J Hack Brian Billups Peter B Guthrie John H Rogers Elizabeth M Muir Thomas N Parks Stanley B Kater | 2000 | Journal of Neuroscience Methods2000，，2： | 1 |
| 18 | Lack of clinical AIDS in SIV-infected sooty mangabeys with significant CD4^sup +^ T cell loss is associated with double-negative T cells显示文摘 | Milush Jeffrey M Mir Kiran D Sundaravaradan Vasudha Gordon Shari N Engram Jessica Cano Christopher A Reeves Jacqueline F Anton Elizabeth O’Neill Eduardo Butler Eboneé Hancock Kathy Cole Kelly S Brenchley Jason M Else James G Silvestri Guido | 2011 | Journal of Clinical Investigation2011，，3： | 1 |
| 19 | An essential role of NF-kappa B in cardioadaptive response to ischemia显示文摘 | ELIZABETH N MORGAN M D EDWARD M | 1999 | Ann Thorac Surg1999，68，2： | 1 |
| 20 | A study of the prevention arid management of pressure sores显示文摘 | Elizabeth P Tolmie Lorraine N Smith | 2002 | Olinical Effectiveness in Nursing2002，6，34： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员